Daily Derm Times: May 22, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Cutibacterium acnes Dominates the Post-Laser Skin Microbiome

Researchers reveal the resilience of Cutibacterium acnes in the skin microbiome post-laser treatments, suggesting its beneficial roles in skin health and aging.

Ascletis Receives FDA Clearance to Advance ASC50, a Novel Oral IL-17 Inhibitor, Into Phase 1 Psoriasis Trial

Ascletis Pharma's investigational new drug application for ASC50 gains FDA clearanc for a phase 1 trial for mild to moderate psoriasis.

Real-World Data on the Adverse Effects of Apremilast and Deucravacitinib for Psoriasis

A recent analysis reveals safety profiles of apremilast and deucravacitinib for psoriasis, highlighting unique adverse events and long-term monitoring needs.

Study Supports Dual Approach for Treatment-Resistant Vitiligo

Discover the promising efficacy and safety of combining platelet-rich plasma with fractional laser therapy for treating vitiligo in adults.

FDA Approves Arcutis’ Roflumilast Foam for Plaque Psoriasis

FDA approves Arcutis' roflumilast foam, a groundbreaking treatment for plaque psoriasis, offering a steroid-free, effective solution for patients aged 12 and older.

Suicide Risk Management Crucial in Dermatological Care

Researchers conducted a clinical review detailing the intersection of dermatology and suicide, explaining why skin conditions lead to increased risk of poor mental health.